Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Resverlogix Corp. T.RVX

Alternate Symbol(s):  RVXCF | T.RVX.W.A

Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.

Recent & Breaking News (TSX:RVX)

Resverlogix Closes $50 Million Private Placement With Hepalink and Eastern Capital

Canada NewsWire July 21, 2015

Resverlogix Closes License Agreement and Enters Into Definitive Stock Purchase Agreement With Hepalink

Canada NewsWire July 8, 2015

Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement

Canada NewsWire June 30, 2015

Resverlogix Officially Attains Phase 3 Status with a European Regulatory Authority

Canada NewsWire June 22, 2015

Resverlogix to Present at the 2015 Bio International Convention

Canada NewsWire June 17, 2015

Resverlogix Reports on the Beneficial Effects of RVX-208 on Glucose Metabolism in Prediabetes Mellitus at the American Diabetes Association's (ADA) Scientific Sessions in Boston, MA

Canada NewsWire June 8, 2015

Resverlogix Presents New Data at 52nd Annual European Renal Association - European Dialysis & Transplant Association Congress (ERA-EDTA)

Canada NewsWire June 1, 2015

Resverlogix (T.RVX) inks licensing and equity deal with China-based Shenzhen Hepalink

Stockhouse Editorial April 27, 2015

Resverlogix and China-based Shenzhen Hepalink Pharmaceutical Co., Ltd. Announce a Combination Licensing and Equity Arrangement

Canada NewsWire April 27, 2015

Resverlogix Receives Two Patents for RVX-208 in China

Canada NewsWire April 7, 2015

Resverlogix Presents at the Prestigious American College of Cardiology 64th Annual Scientific Session & Expo (ACC.15)

Canada NewsWire March 16, 2015

Resverlogix Collaborates with Emerald Logic to Identify Factors Driving Drug Response and Efficacy in Phase 2 Program

Canada NewsWire March 4, 2015

Resverlogix Presents at BIO CEO & Investor Conference

Canada NewsWire February 10, 2015

Resverlogix Presents at Biotech Showcase During JP Morgan Week

Canada NewsWire January 14, 2015

Resverlogix Names Michael Sweeney, M.D., as Senior Vice President of Clinical Development

Canada NewsWire November 3, 2014

Resverlogix Announces Annual General Meeting Voting Results

Canada NewsWire October 8, 2014

Resverlogix Corporate Update Conference Call & Webcast Announcement

Canada NewsWire October 1, 2014

RVX-208 Leads to a 77% Relative Risk Reduction of Major Adverse Cardiovascular Events (MACE) in Patients with Diabetes Mellitus

Canada NewsWire September 2, 2014

Resverlogix Corp. Closes Additional $30 million from Citibank Loan

Canada NewsWire August 15, 2014

Resverlogix Corp. Shareholders Approve Additional $30 million from Citibank Loan

Canada NewsWire August 13, 2014